Cisplatin-based therapy: A neurological and neuropsychological review

Psycho-Oncology

Volumn 9, Issue 1, 2000, Pages 29-39

  Troy, L ^a,b   McFarland, K ^a   Littman Power, S ^a   Kelly, B J ^b   Walpole, E T ^b   Wyld, D ^b   Thomson, D ^c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; BLEOMYCIN; CISPLATIN; DEXAMETHASONE; ETOPOSIDE; GRANISETRON; INORGANIC SALT; LEAD; MANNITOL; MERCURY; METOCLOPRAMIDE; ONDANSETRON; PLATINUM COMPLEX; PROCHLORPERAZINE; VINBLASTINE; VINCA ALKALOID;

AUTONOMIC NEUROPATHY; CANCER; CANCER CHEMOTHERAPY; COGNITION; DOSE RESPONSE; EYE DISEASE; HUMAN; NEPHROTOXICITY; NEUROPSYCHOLOGY; NEUROTOXICITY; OTOTOXICITY; PERIPHERAL NEUROPATHY; QUALITY OF LIFE; REVIEW; SEIZURE; SURVIVAL; VOMITING; WELLBEING;

ANTINEOPLASTIC AGENTS; CISPLATIN; FEMALE; HUMANS; MALE; NEOPLASMS; NERVOUS SYSTEM DISEASES; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TESTS; SUBSTANCE-RELATED DISORDERS;

EID: 0033962792     PISSN: 10579249     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1611(200001/02)9:1<29::AID-PON428>3.0.CO;2-Z     Document Type: Review

References (119)

1. Alberts, D.S. and Noel, J.K. (1995) Cisplatin-associated neurotoxicity: can it be prevented? Anti-Cancer Drugs 6, 369-383.
2. Anderson, A. (1982) Neurotoxic follies. Psychol. Today July, 30-44.
3. Bassetto, M.A., Pasini, F., Franceschi, T., Mustacchi, G. and Getto, G.L. (1995) Extragonadal germ cell tumour: a clinical study. Anticancer Res. 15, 2751-2754.
4. Berenbaum, S.A., Korman, K. and Leveroni, C. (1995) Early hormones and sex differences in cognitive abilities. Learn. Individ. Differ. 7, 303-321.
5. Berg, R.A., Ch'ien, L.T., Lancaster, W., Williams, S. and Cummins, J. (1983) Neuropsychological sequelae of postradiation somnolence syndrome. J. Dev. Behav. Pediatr. 4, 103-107.
6. Berger, C.C., Bokemeyer, C., Schneider, M., Kuczyk, M.A. and Schmoll, H.J. (1995) Secondary Raynaud's Phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur. J. Cancer 31A, 2229-2238.
7. Herman, I.J. and Mann, M.P. (1980) Seizures and transient cortical blindness associated with cisplatinum (II) diaminedichloride (PDD) therapy in a thirty-year old man. Cancer 45, 764-766.
8. Blijham, G.H. (1993) Prevention and treatment of organ toxicity during high-dose chemotherapy: an overview. Anti-Cancer Drugs 4, 527-533.
9. Bloom, J.R., Stewart, S.L. Johnston, M. and Banks, P. (1998) Intrusiveness of illness and quality of life in young women with breast cancer. Psycho-Oncology 7, 89-100.
10. Boivin, M.J. and Giordani, B. (1995) A risk evaluation of the neuropsychological effects of childhood lead toxicity. Dev. Neuropsychol. 11, 157-180.
11. Bonnem, E.M., Litterst, C.L. and Smith, F.P. (1982) Platinum concentrations in human glioblastoma multiforme following the use of cisplatin. Cancer Treat. Report. 66, 1661-1663.
12. Braun, C.M.T., Daigneault, S. and Gilbert, B. (1989) Colour discrimination testing reveals early printshop solvent neurotoxicity better than a neuropsychological test battery. Arch. Clin. Neuropsych. 4, 1-13.
13. Broverman, D.M., Broverman, I.K., Vogel, W., Palmer, R. and Klaiber E.L. (1964) Cognitive style and physical development. Child Dev. 35, 1343-1359.
14. Brown, R.T. and Madan-Swain, A. (1993) Cognitive, neuropsychological, and academic sequelae in children with leukemia. J. Learn. Disabil. 26, 74-90.
15. Butler, R.W. and Copeland, D.R. (1993) Neuropsychological effects of central nervous system prophylactic treatment in childhood leukemia: methodological considerations. J. Pediatr. Psychol. 18, 319-338.
16. Carey, M.P. and Burish, T.G. (1988) Etiology and treatment of the psychological side effects associated with cancer chemotherapy: a critical review and discussion. Psychol. Bull. 104, 307-325.
17. Cattaneo, M.T., Filipazzi, V., Piazza, E., Damiani, E. and Mancarella, G. (1988) Transient blindness and seizure associated with cisplatin therapy. J. Cancer Res. Clin. Oncol. 114, 528-530.
18. Cavaletti, G., Bogliun, G., Marzorati, L., Tredici, G., Colombo, N., Parma, G. and Miceli, M.D. (1994) Long-term peripheral neurotoxicity of cisplatin in patients with successfully treated epithelial ovarian cancer. Anticancer Res. 14, 1287-1292.
19. Cavaletti, G., Marzorati, L., Bogliun, G., Colombo, N., Marzola, M., Pittelli, M.R. and Tredici, G. (1992) Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. Cancer 69, 203-207.
20. Cavaletti, G., Petruccioli, M.G., Tredici, G., Marmiroli, P., Barajon, I., Fabbrica, D. and Di Francesco, A. (1991) Effects of repeated administration of low doses of cisplatin on the rat nervous system. Int. J. Tissue React. 13, 151-157.
21. Cersosimo, R.J. (1989) Cisplatin neurotoxicity. Cancer Treat. Rev. 16, 195-211.
22. Christiansen, K. and Knussmann, R. (1987) Sex hormones and cognitive functioning in men. Neuropsychobiology 18, 27-36.
23. Ciesielski, D.T. and Knight, J.E. (1994) Cerebellar abnormality in autism: a nonspecific effect of early brain damage. Special Issue: 75th Anniversary of the Nencki Institute. Acta Neurobiol. Exp. 54, 151-154.
24. Clark, A.W., Parhad, I.M., Griffin, J.W. and Price, D.L. (1980) Neurotoxicity of cis-platinum: pathology of the central and peripheral nervous systems. Neurology 30, 429.
25. Copeland, D.R., Dowell, R.E., Fletcher, J.M. and Bordeaux, J.D. (1988) Neuropsychological effects of childhood cancer treatment. J. Child Neurol. 3, 53-62.
26. Culine, S. and Droz, J. (1996) Adjuvant chemotherapy in pathologic stage II nonseminomatous testicular cancer: are two cycles of etoposide-cisplatin a standard option? J. Clin. Oncol. 14, 2187-2190.
27. Culine, S., Theodore, C., Terrier-Lacombe, M.J. and Droz, J.P. (1996) Primary chemotherapy in patients with nonseminomatous germ cell tumors of the testis and biological disease only after orchiectomy. J. Urol. 155, 1296-1298.
28. Davey, V.D. and Biederman, G.B. (1998) Conditioned antisickness: indirect evidence from rats and direct evidence from ferrets that conditioning alleviates drug-induced nausea and emesis. J. Exp. Psychol.: Anim. Behav. Process. 24, 483-491.
29. Davis, B.D., Fernandez, F., Adams, F. and Holmes, V.F. (1987) Diagnosis of dementia in cancer patients. Psychosomatics 28, 175-179.
30. De Koning, P., Neijy, J.P., Jennekens, F.G.I. and Gispen, W.H. (1987) Evaluation of cis-diammine-dichloroplatinum (II) (Cisplatin) neurotoxicity in rats. Toxicol. Appl. Pharmacol. 89, 81-87.
31. Discalzi, G., Fabbro, D., Meliga, F., Mocellini, A. and Capellaro, F. (1993) Effects of occupational exposure to mercury and lead on brainstem auditory evoked potentials. Int. J. Psychophysiol. 14, 21-25.
32. Dominguez-Ortega, L., Cubedo-Cervera, R., Cortes-Funes, H. and Diaz-Gallego, E. (1996) Sleep protects against chemotherapy induced emesis. Cancer 77, 1566-1570.
33. Duffner, P.K., Horowitz, M.E., Krischer, J.P., Friedman, H.S., Burger, P.C., Cohen, M.E., Sanford, R.A., Mulhern, R.K., James, H.E., Freeman, C.R., Seidel, F.G. and Kun, L.E. (1993) Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumours. New Engl. J. Med. 328, 1725-1731.
34. Echeverria, D., Heyer, N.J., Martin, M.D., Naleway, C.A., Woods, J.S. and Bittner, A.C. (1995) Behavioral effects of low-level exposure to Hg among dentists. Neurotoxicol. Teratol. 17, 161-168.
35. Elderson, A., van der Hoop, R.G., Haanstra, W., Neijt, J.P., Gispen, W.H. and Jennekens, F.G.I. (1989) Vibration perception and thermoperception as quantitative measurements in the monitoring of cisplatin induced neurotoxicity. J. Neurolog. Sci. 93, 167-174.
36. El-Shazly, M.O., Afify, M.M.H. and El-Dieb, M.K. (1989) Histopathological study into side-effect toxicity of some drugs used in treatment of cancer. Arch. Exp. Vet. Med. 43, 319-326.
37. Ferrel, B.R., Grant, M.M., Funk, B., Otis-Green, S. and Garcia, N. (1997) Quality of life in breast cancer survivors as identified by focus groups. Psycho-Oncology 6, 13-23.
38. Fletcher, J.M. and Copeland, D.R. (1988) Neurobehavioural effects of central nervous system prophylactic treatment of cancer in children. J. Clin. Exp. Neuropsychol. 10, 495-537.
39. Fossa, S.D., Lehne, G., Heimdal, K. and Theodorsen, L. (1995) Clinical and biochemical long-term toxicity after postoperative cisplatin-based chemotherapy in patients with low-stage testicular cancer. Oncology 52, 300-305.
40. Fossen, A. (1995) Sequelae of brain tumour treatment in children. Tidsskr. Norsk Psykol. 32, 232-238.
41. Frustaci, S., Barzan, L., Comoretto, R., Tumoio, S., Lo Re, G. and Monfardini, S. (1987) Local neurotoxicity after intra-arterial cisplatin in head and neck cancer. Cancer Treat. Report. 71, 257-259.
42. Gaedeke, J., Bokemeyer, C., Mengs, U., Stolte, H. and Lentzen, H. (1996) Cisplatin nephrotoxicity and protection by silibinin. Nephrol. Dial. Transpl. 11, 55-62.
43. Garcia, P.A., Narbona, G.J., Sierrasesumaga, L. and Ventallo, A. (1993) Neuropsychological outcome of children after radiotherapy for intracranial tumours: 20th Meeting of the European Society of Neurology and Pediatrics (1991, Brussels). Dev. Med. Child Neurol. 35, 139-148.
44. Gerl, A., Clemm, C., Lamerz, R. and Wilmanns, W. (1996) Cisplatin-based chemotherapy of primary extragonadal germ cell tumors. Cancer 77, 526-532.
45. Gordon, H.W. and Lee, P.A. (1986) The relationship between gonadotropins and visuospatial function. Neuropsychologia 24, 563-576.
46. Gralla, R.J., Rittenberg, C., Peralta, M., Lettow, L. and Cronin, M. (1996) Cisplatin and emesis: aspects of treatment and a new trial for delayed emesis using oral dexamethasone plus ondansetron beginning 16 hours after cisplatin. Oncology 53(Suppl. 1), 86-91.
47. Gregg, R.W., Molepo, J.M., Monpetit, V.J.A., Mikael, N.Z., Redmond, D., Gadia, M. and Stewart, D.J. (1992) Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J. Clin. Oncol. 10, 795-803.
48. Grunberg, S.M., Sonka, S., Stevenson, L.L. and Muggia, F.M. (1989) Progressive paresthesias after cessation of therapy with very high-dose cisplatin. Cancer Chemother. Pharmacol. 25, 62-64.
49. Hamers, F.P.T., Gispen, W.H. and Neijt, J.P. (1991) Neurotoxic side-effects of cisplatin. Eur. J. Cancer 27, 372-376.
50. Hansen, S.W. (1990) Autonomic neuropathy after treatment with cisplatin, vinblastine, and bleomycin for germ cell cancer. Br. J. Med. 300, 511-512.
51. Hansen, S.W. (1992) Late-effects after treatment for germ-cell cancer with cisplatin, vinblastine, and bleomycin. Dan. Med. Bull. 39, 391-399.
52. Hansen, S.W., Helweg-Larsen, S. and Trojaborg, W. (1989) Long-term neurotoxicity in patients treated with cisplatin, vinblastine, and bleomycin for metastatic germ cell cancer. J. Clin. Oncol. 7, 1457-1461.
53. Hartman, D.E. (1995) Neuropsychological Toxicology: Identification and Assessment of Human Neurotoxic Syndromes. Plenum Press, New York.
54. Hayes, D.M., Cvitkovic, E., Golbey, R.B., Scheiner, E., Helson, L. and Krakoff, I.H. (1977) High dose cis-platinum diammine dichloride. Cancer 39, 1372-1381.
55. Hein, H.O., Suadicani, P. and Gyntelberg, F. (1990) Mixed solvent exposure and cerebral symptoms among active and retired workers: an epidemiological investigation of 3387 men aged 53-75 years. Acta Neurol. Scand. 81, 97-102.
56. Hesketh, P. (1996) Management of cisplatin-induced delayed emesis. Oncology 53(Suppl. 1), 73-77.
57. Holland, J.C., Passik, S., Kash, K.M., Russak, S.M., Gronert, M.K., Sison, A., Lederburg, M., Fox, B. and Baider, L. (1999) The role of religious and spiritual beliefs in coping with malignant melanoma. Psycho-Oncology 8, 14-26.
58. Holland, J.C., Romano, S.J., Heiligenstein, J.H., Tepner, R.G. and Wilson, M.G. (1998) A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psycho-Oncology 7, 291-300.
59. Holleran, W.M. and De Gregorio, M.W. (1988) Evolution of high-dose cisplatin. Investig. New Drugs 6, 135-142.
60. Hussain, M., Wozniak, A.J. and Edelstein, M.B. (1993) Neurotoxicity of antineoplastic agents. Clin. Rev. Oncol./Hematol. 14, 61-75.
61. Ilveskoski, I., Saarinen, U.M., Wiklund, T., Perkkio, M., Salmi, T.T., Lanning, M., Makipernaa, A. and Pihko, H. (1996) Ototoxicity in children with malignant brain tumours treated with the '8 in 1' chemotherapy protocol. Med. Pediatr. Oncol. 27, 26-31.
62. Inbar, M., Merimsky, O., Wigler, N. and Chaltchik, S. (1992) Cisplatin-related Lhermitte's sign. Anti-Cancer Drugs 3, 375-377.
63. Johnston, C.W. (1985) Language ability in children treated with central nervous system prophylaxis for acute lymphocytic leukemia. Int. J. Clin. Neuropsychol. 7, 25-28.
64. Johnston, C.W., Nesbit, M. and Robison, L. (1986) Neuropsychological functioning in a long-term survivor of childhood acute lymphocytic leukemia: a case study with comparison to a nonafflicted twin sibling. Dev. Neuropsychol. 2, 113-123.
65. Kaasa, S., Olsnes, B.T. and Mastekaasa, A. (1988) Neuropsychological evaluation of patients with inoperable non-small cell lung cancer treated with combination chemotherapy or radiotherapy. Acta Oncol. 27, 241-246.
66. Kedar, A., Cohen, M.E. and Freeman, A.I. (1978) Peripheral neuropathy as a complication of cis-dichlorodiammineplatinum (II) treatment: a case report. Cancer Treat. Report. 62, 819-821.
67. Kelland, L.R. (1993) New platinum antitumour complexes. Crit. Rev. Oncol./Hematol. 15, 191-219.
68. Kelly, M.A., Gorelick, P.B. and Mirza, D. (1992) The role of drugs in the etiology of stroke. Clin. Neuropharmacol. 15, 249-275.
69. Kelty, P., Frazier, H., O'Connell, K. and Ghosh, B.C. (1996) Germ cell testis cancer: 15 year review. J. Surg. Oncol. 62, 30-33.
70. Komnenich, P., Lane, D.M., Dickey, R.P. and Stone, S.C. (1978) Gonadal hormones and cognitive performance. Physiol. Psychol. 6, 115-120.
71. Leibbrandt, M.E., Wolfgang, G.H., Metz, A.L., Ozobia, A.A. and Haskins, J.R. (1995) Critical subcellular targets of cisplatin and related platinum analogs in rat renal proximal tubule cells. Kidney Int. 48, 761-770.
72. Lewis, C. (1994) A review of the use of chemoprotectants in cancer chemotherapy. Drug Saf. 11, 153-162.
73. Lezak, M.D. (1984) Neuropsychological assessment in behavioral toxicology: developing techniques and interpretive issues. Scand. J. Work Environ. Health 10(Suppl 1), 25-29.
74. List, M.A., Siston, A., Haraf, D., Schumm, P., Kies, M., Stenson, K. and Vokes, E.E. (1999) Quality of life and performance in advanced head and neck cancer patients on concomitant chemoradiotherapy: a prospective examination. J. Clin. Oncol. 17, 1020-1028.
75. Macdonald, D.R. (1991) Neurologic complications of chemotherapy. Neurol. Clin. 9, 955-967.
76. Maiese, K., Walker, R.W., Gargan, R. and Victor, J.D. (1992) Intra-arterial cisplatin-associated optic and otic toxicity. Arch. Neurol. 49, 83-86.
77. Matsui, K., Fukuoka, M., Takada, M., Kusunoki, Y., Yana, T., Tamura, K., Yoshida, T., Iida, K., Harashima, T., Tsukada, H., Ushijima, S., Miyawaki, H. and Masuda, N. (1996) Randomised trial for the prevention of delayed emesis in patients receiving high-dose cisplatin. Br. J. Cancer 73, 217-221.
78. McKeage, M.J. (1995) Comparative adverse effect profiles of platinum drugs. Drug Saf. 13, 228-244.
79. Merrin, C. (1977) Treatment of advanced carcinoma of the prostate (stage D) with infusion of cis-diamminedicholorplatinum (CPDD) and mannitol. Abstracts of the 68th Annual Meeting of the AACR, Denver, Colorado, May.
80. Middelboe, T., Ovesen, L., Mortensen, E.L. and Bech, P. (1994) Depressive symptoms in cancer patients undergoing chemotherapy: a psychometric analysis. Psychother. Psychosomat. 61, 171-177.
81. Mollman, J.E. (1990) Cisplatin neurotoxicity. New Eng. J. Med. 322, 126-127.
82. Moore, B.D., Ater, J.L. and Copeland, D.R. (1992) Improved neuropsychological outcome in children with brain tumours diagnosed during infancy and treated without cranial irradiation. J. Child Neurol. 7, 281-290.
83. Morrow, L.A., Robin, N., Hodgson, M.J. and Kamis, H. (1992) Assessment of attention and memory efficiency in persons with solvent neurotoxicity. Neuropsychology 30, 911-922.
84. Nass, R.D. (1993) Sex differences in learning abilities and disabilities. Ann. Dyslexia 43, 61-77.
85. Neuwelt, E.A., Glasberg, M., Frenkel, E. and Barnett, P. (1983) Neurotoxicity of chemotherapeutic agents after blood-brain barrier modification: neuropathological studies. Ann. Neurol. 14, 316-324.
86. Nolte, J. (1993) The Human Brain: An Introduction to its Functional Anatomy (3rd edn.). Mosby Year Book, St. Louis, MO.
87. Olivi, A., Gilbert, M., Duncan, K.L., Corden, B., Lenartz, D. and Brem, H. (1993) Direct delivery of platinum-based antineoplastics to the central nervous system: a toxicity and ultrastructural study. Cancer Chemother. Pharmacol. 31, 449-454.
88. Ossi, M., Anderson, E. and Freeman, A. (1996) 5-HT3 receptor antagonists in the control of cisplatin-induced delayed emesis. Oncology 53(Suppl. 1), 78-85.
89. Payne, D.K., Lundberg, J.C., Brennan, M.F. and Holland, J.C. (1997) A psychosocial intervention for patients with soft tissue sarcoma. Psycho-Oncology 6, 65-72.
90. Pirovano, C., Balzarini, A., Bohm, S., Oriana, S., Spatti, G.B. and Zunino, F. (1992) Peripheral neurotoxicity following high-dose cisplatin with glutathione: clinical and neuropsychological assessment. Tumori 78, 253-257.
91. Potkul, R.K., Gondal, J., Bitterman, P., Dretchen, K.L. and Rahman, A. (1991) Toxicities in rats with free versus liposomal encapsulated cisplatin. Am. J. Obstet. Gynecol. 164, 652-657.
92. Ravi, R., Somani, S.M. and Rybak, L.P. (1995) Mechanism of cisplatin ototoxicity: antioxidant system. Pharmacol. Toxicol. 76, 386-394.
93. Redd, W.H., Silberfarb, P.M., Anderson, B.L., Andrykowski, M.A., Bovbjerg, D.H., Burish, T.G., Carpenter, P.J., Cleeland, C., Dolgin, M. and Levy, S.M. (1991) Physiologic and psychobehavioral research in oncology. Cancer 67(Supplement), 813-822.
94. Reite, M., Sheeder, J., Teale, P., Richardson, M., Adams, M. and Simon, J. (1995) MEG based brain laterality: sex differences in normal adults. Neuropsychologia 33, 1607-1616.
95. Roelofs, R.I., Hruskesky, W., Rogin, J. and Rosenberg, L. (1984) Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology 34, 934-938.
96. Roila, F. (1996) Control of acute cisplatin-induced emesis over repeat courses of chemotherapy. Oncology 53(Suppl. 1), 65-72.
97. Rosenberg, B. (1985) Fundamental studies with cis-platin. Cancer 55, 2303-2316.
98. Rosenberg, B., Van Camp, L. and Krigas, T. (1965) Inhibition of cell division in Escherichia coli by electrolysis produces from a platinum electrode. Nature 205, 698-699.
99. Rosenberg, B., Van Camp, L., Trosko, J.E. and Mansour, V.H. (1969) Platinum compounds: a new class of potent antitumour agents. Nature 222, 385-386.
100. Siimes, M.A., Ropponen, P., Aalberg, V., Komulainen, J. and Rautomen, J. (1993) Prolactinemia in adolescent males surviving malignancies in childhood: impaired dating activity. J. Adolesc. Health 14, 543-547.
101. Silberfarb, P. (1983) Chemotherapy and cognitive defects in cancer patients. Annu. Rev. Med. 34, 35-46.
102. Srivastava, R.C., Farookh, A., Ahmed, N., Misra, M., Hasan, S.K. and Hussain, M.M. (1995) Reduction of cis-platinum induced nephrotoxicity by zinc histidine complex: the possible implication of nitric oxide. Biochem. Mol. Biol. Int. 36, 855-862.
103. Stiles, K.M. and Bellinger, D.C. (1993) Neuropsychological correlates of low-level lead exposure in school-age children: a prospective study. Neurotoxicol. Teratol. 15, 27-35.
104. Swerdloff, R.S., Wang, C., Hines, M. and Gorski, R. (1992) Effects of androgens of the brain and other organs during development and aging. Psychoneuroendocrinology 17, 375-383.
105. Thompson, S.W., Davies, L.E., Kornfeld, M., Hilgers, R.D. and Standefer, J.C. (1984) Cisplatin neuropathy: clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 54, 1269-1275.
106. Tuxen, M.K. and Hansen, S.W. (1994) Complications of treatment: neurotoxicity secondary to antineoplastic drugs. Cancer. Treat. Rev. 20, 191-214.
107. Van Basten, J.P., Schrafford-Koops, H., Sleijfer, D.T., Pras, E., Van Driel, D.F. and Hoekstra, H.J. (1997) Current concepts about testicular cancer. Eur. J. Surg. Oncol. 23, 354-360.
108. Van der Wall, E., Beijnen, J.H. and Rodenhuis, S. (1995) High-dose chemotherapy regimens for solid tumors. Cancer Treat. Rev. 21, 105-132.
109. Verweij, J., de Wit, R. and Mulder, P.H.M. (1996) Optimal control of acute cisplatin-induced emesis. Oncology 53(Suppl. 1), 56-64.
110. Von Hoff, D.D., Schilsky, R., Reichert, C.M., Reddick, R.L., Rozenweig, M., Young, R.C. and Muggia, F.M. (1979) Toxic effects of cis-dichlorodiammine-platinum (II) in man. Cancer Treat. Report. 63, 1527-1531.
111. Wallace, H.J. and Higby, D.J. (1974) Phase I evaluation of cis-diamminedichloroplatinum and a combination of DDP plus adriamycin, in Platinum Coordination Compresses in Cancer Chemotherapy (T.A. Connors and J.J. Roberts Eds). Springer-Verlag, Heidelberg.
112. Walther, P.J., Rossitch, E. and Bullard, D.E. (1987) The development of Lhermitte's sign during cisplatin chemotherapy. Cancer 60, 2170-2172.
113. Weiss, B. (1983) Behavioral toxicology and environmental health science. Opportunity and challenge for psychology. Am. Psychol., November, 1174-1187.
114. Wennberg, A. (1994) Neurotoxic effects of selected metals. Scand. J. Work Environ. Health 20, 65-71.
115. Wennberg, A., Iregren, A., Struwe, G., Cizinsky, G., Hagman, M. and Johansson, L. (1991) Manganese exposure in steel smelters a health hazard to the nervous system. Scand. J. Work Environ. Health 17, 255-262.
116. White, R.F., Feldman, R.G. and Proctor, S.P. (1992) Neurobehavioral effects of toxic exposures, in Clinical Syndromes in Adult Neuropsychology: The Practitioner's Handbook (R.F. White Ed.). B.V. Elsevier Science Publishers, Amsterdam, pp. 1-51.
117. White, R.F., Feldman, R.G. and Travers, P. (1990) Neurobehavioral effects of toxicity due to metals, solvents, and insecticides. Clin. Neuropharmacol. 13, 392-412.
118. Wieneke, M.H. and Dienst, E.R. (1995) Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-Oncology 4, 61-66.
119. Yeates, K.O. and Mortensen, M.E. (1994) Acute and chronic neuropsychological consequences of mercury vapor poisoning in two early adolescents. J. Clin. Exp. Neuropsychol. 16, 209-222.